Émilie Varey

Inserm — France

Medicine · Health Sciences

14h-index702citations63works10.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Immunotherapy and Biomarkers(32), Melanoma and MAPK Pathways(24), Cutaneous Melanoma Detection and Management(23), Immunotherapy and Immune Responses(21), CAR-T cell therapy research(17)

Publications63 total

Implementing a Biomedical Data Warehouse From Blueprint to Bedside in a Regional French University Hospital Setting: Unveiling Processes, Overcoming Challenges, and Extracting Clinical Insight
JMIR Medical Informatics·2024· 10 citedOpen Access
Machine learning algorithm to predict response to immunotherapy in real-life settings for patients with advanced melanoma
European Journal of Dermatology·2023· 3 cited
Panniculitis does not predict clinical response in patients with advanced melanoma under targeted therapy
European Journal of Dermatology·2023
Analysis of cost-effectiveness of chemotherapeutic agents and new therapies for the management of unresectable and metastatic melanoma
European Journal of Dermatology·2023· 1 cited
Figure S1 from Emergence of High-Avidity Melan-A–Specific Clonotypes as a Reflection of Anti–PD-1 Clinical Efficacy
2023Open Access
Data from Emergence of High-Avidity Melan-A–Specific Clonotypes as a Reflection of Anti–PD-1 Clinical Efficacy
2023Open Access
Supplemental figure legends from Emergence of High-Avidity Melan-A–Specific Clonotypes as a Reflection of Anti–PD-1 Clinical Efficacy
2023Open Access
Figure S4 from Emergence of High-Avidity Melan-A–Specific Clonotypes as a Reflection of Anti–PD-1 Clinical Efficacy
2023Open Access
Figure S3 from Emergence of High-Avidity Melan-A–Specific Clonotypes as a Reflection of Anti–PD-1 Clinical Efficacy
2023Open Access
Figure S2 from Emergence of High-Avidity Melan-A–Specific Clonotypes as a Reflection of Anti–PD-1 Clinical Efficacy
2023Open Access
Figure S1 from Emergence of High-Avidity Melan-A–Specific Clonotypes as a Reflection of Anti–PD-1 Clinical Efficacy
2023Open Access
Figure S4 from Emergence of High-Avidity Melan-A–Specific Clonotypes as a Reflection of Anti–PD-1 Clinical Efficacy
2023Open Access
Data from Emergence of High-Avidity Melan-A–Specific Clonotypes as a Reflection of Anti–PD-1 Clinical Efficacy
2023Open Access
Figure S2 from Emergence of High-Avidity Melan-A–Specific Clonotypes as a Reflection of Anti–PD-1 Clinical Efficacy
2023Open Access
Figure S3 from Emergence of High-Avidity Melan-A–Specific Clonotypes as a Reflection of Anti–PD-1 Clinical Efficacy
2023Open Access
Supplemental figure legends from Emergence of High-Avidity Melan-A–Specific Clonotypes as a Reflection of Anti–PD-1 Clinical Efficacy
2023Open Access
Epidemiology and characteristics of acral lentiginous melanoma compared to lentigo melanoma in France: a multicentric retrospective study from the French cohort RIC-Mel database
European Journal of Dermatology·2022· 3 cited
Melanoma and intellectual disability: do prognostic factors at diagnosis differ from general population?
Journal of Intellectual Disability Research·2022· 3 cited
Données en vie réelle des inhibiteurs de check-point dans le mélanome métastatique
Annales de Dermatologie et de Vénéréologie - FMC·2021
Prise en charge des patients atteints de mélanome de stade III ou IV réséqué depuis l’arrivée de l’immunothérapie et de la thérapie ciblée en situation adjuvante en vie réelle
Annales de Dermatologie et de Vénéréologie - FMC·2021
page 1 of 4Next →

Frequent Co-authors

Brigitte Dréno(44), Amir Khammari(41), Anne‐Chantal Knol(12), G. Quéreux(12), Jean‐Michel Nguyen(11), M.‐T. Leccia(11), L. Peuvrel(9), Stéphane Dalle(9), S. Dalac‐Rat(9), Nicolás Meyer(9), B. Guillot(9), F. Skowron(9), Laurent Mortier(8), Caroline Dutriaux(8), Célèste Lebbé(8), M. Saint‐Jean(7), Sylvain Simon(7), Virginie Vignard(7), Tiphaine Parrot(7), Nadine Gervois(7)